Long-term depot antipsychotics. A risk-benefit assessment

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Covert noncompliance is a significant challenge in managing schizophrenia.
• Oral antipsychotic medications exhibit considerable individual variation in bioavailability and metabolism.
• Maintaining consistent medication adherence is crucial for preventing relapse and hospitalization.

Purpose of the Study:

• To evaluate the advantages and disadvantages of depot antipsychotic medication compared to oral formulations.
• To assess the impact of depot antipsychotics on patient compliance, relapse rates, and pharmacokinetic profiles.
• To provide guidance for clinicians in selecting appropriate maintenance antipsychotic therapy for schizophrenia.

Main Methods:

• Review of clinical studies and pharmacokinetic data comparing depot and oral antipsychotic treatments.
• Analysis of patient compliance data in monitored management programs.
• Assessment of adverse effect profiles and dose-adjustment strategies for depot antipsychotics.

Main Results:

• Depot antipsychotics significantly improve compliance by allowing immediate identification of missed doses.
• Depot formulations offer reduced pharmacokinetic variability and more predictable plasma concentrations compared to oral drugs.
• Depot treatment demonstrates comparable or superior efficacy to oral medication in preventing relapse, with no significant difference in adverse effect profiles.

Conclusions:

• Depot antipsychotic medication is a valuable tool for enhancing treatment adherence and reducing relapse in schizophrenia.
• The predictable pharmacokinetics and improved compliance associated with depot injections offer greater clinical control.
• The choice between depot and oral antipsychotics should primarily consider the individual patient's risk of noncompliance.